Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03332017 · ClinicalTrials.gov registry record · Phase 2
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
A Phase 2 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 2
- Development phase
- 217
- Enrollment target
NCT03332017 is a Phase 2 study that has completed, run by BeiGene. The registered enrollment target is 217 participants.
The verdict
NCT03332017, a Phase 2 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 217 participants
- Enrollment target
Study Summary
This clinical study examined the safety and efficacy of the combination of zanubrutinib and obinutuzumab versus obinutuzumab alone in adults with follicular lymphoma whose disease returned after or did not respond to prior therapy.
Interventions
- DRUG Zanubrutinib
- DRUG Obinutuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2017-11-14 |
| Est. Completion | 2024-12-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03332017
The ClinicalTrials.gov registry entry for NCT03332017 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zanubrutinib is the first listed.
NCT03332017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03332017 about?
NCT03332017 is a clinical study titled "A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma". This clinical study examined the safety and efficacy of the combination of zanubrutinib and obinutuzumab versus obinutuzumab alone in adults with follicular lymphoma whose disease returned after or did not respond to prior therapy.
What is the current status of trial NCT03332017?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 217 participants. The study started on 2017-11-14. Estimated completion is 2024-12-27.
What interventions are being tested in trial NCT03332017?
The interventions under investigation include: Zanubrutinib (DRUG), Obinutuzumab (DRUG).
Who is sponsoring clinical trial NCT03332017?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.